A number of leading pharmaceutical companies – include Pfizer, Bayer, Roche and AstraZeneca - have pre-released data regarding investigation cancer drugs that are due to be presented at the forthcoming 47th Annual American Society of Clinical Oncology (ASCO) meeting in Chicago, which takes place June 3-7, 2011.
Axitinib in kidney cancer
Global drugs behemoth Pfizer (NYSE: PFE) announced data from the pivotal Phase III AXIS 1032 trial, showing that in patients with previously treated advanced renal cell carcinoma (RCC), axitinib significantly extended progression-free survival (PFS) [HR=0.665, 95% CI; P<0.0001], with a median PFS of 6.7 months (95%CI, 6.3-8.6), compared with 4.7 months (4.6-5.6) for those treated with sorafenib, a standard of care for this patient population. PFS was significantly longer in axitinib-treated patients compared to those treated with sorafenib, regardless of prior therapy with Sutent (sunitinib malate) or cytokines.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze